Your browser doesn't support javascript.
loading
Designing three-level cluster randomized trials to assess treatment effect heterogeneity.
Li, Fan; Chen, Xinyuan; Tian, Zizhong; Esserman, Denise; Heagerty, Patrick J; Wang, Rui.
Afiliación
  • Li F; Department of Biostatistics, Yale University School of Public Health, New Haven, CT 06510, USA.
  • Chen X; Department of Mathematics and Statistics, Mississippi State University, MS 39762, USA.
  • Tian Z; Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, Pennsylvania State University, Hershey, PA 17033, USA.
  • Esserman D; Department of Biostatistics, Yale University School of Public Health, New Haven, CT 06510, USA.
  • Heagerty PJ; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
  • Wang R; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA and Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA 02215, USA.
Biostatistics ; 24(4): 833-849, 2023 10 18.
Article en En | MEDLINE | ID: mdl-35861621
Cluster randomized trials often exhibit a three-level structure with participants nested in subclusters such as health care providers, and subclusters nested in clusters such as clinics. While the average treatment effect has been the primary focus in planning three-level randomized trials, interest is growing in understanding whether the treatment effect varies among prespecified patient subpopulations, such as those defined by demographics or baseline clinical characteristics. In this article, we derive novel analytical design formulas based on the asymptotic covariance matrix for powering confirmatory analyses of treatment effect heterogeneity in three-level trials, that are broadly applicable to the evaluation of cluster-level, subcluster-level, and participant-level effect modifiers and to designs where randomization can be carried out at any level. We characterize a nested exchangeable correlation structure for both the effect modifier and the outcome conditional on the effect modifier, and generate new insights from a study design perspective for conducting analyses of treatment effect heterogeneity based on a linear mixed analysis of covariance model. A simulation study is conducted to validate our new methods and two real-world trial examples are used for illustrations.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proyectos de Investigación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Biostatistics Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proyectos de Investigación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Biostatistics Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos